Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial

被引：5

作者：

Flume, Patrick A. ^{[1
]}

Harris, R. Scott ^{[2
]}

Paz-Diaz, Hildegarde ^{[2
]}

Ahluwalia, Neil ^{[2
]}

Higgins, Mark ^{[3
]}

Campbell, Daniel ^{[2
]}

Berhane, Indrias ^{[2
]}

Shih, Judy L. ^{[2
]}

Sawicki, Gregory ^{[4
]}

机构：

[1] Med Univ South Carolina, MUSC Hlth Cyst Fibrosis Ctr, 96 Jonathan Lucas St, Charleston, SC 29425 USA

[2] Vertex Pharmaceut Inc, 50 Northern Ave, Boston, MA USA

[3] Vertex Pharmaceut Europe Ltd, 2 Kingdom St, London W2 6BD, England

[4] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, 300 Longwood Ave, Boston, MA USA

来源：

JOURNAL OF CYSTIC FIBROSIS | 2023年 / 22卷 / 03期

关键词：

Cystic fibrosis; Ivacaftor; Tezacaftor; F508del; Phase; 3; IVACAFTOR; LUMACAFTOR; PROGRESS; PHASE-3;

D O I：

10.1016/j.jcf.2022.12.006

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: Study 661-110 (EXTEND) is a phase 3, open-label, three-part rollover study designed to assess the long-term safety and efficacy of tezacaftor/ivacaftor (TEZ/IVA) in participants aged & GE;12 years homozygous for F508del (F/F) or heterozygous for F508del and a residual function mutation (F/RF). TEZ/IVA was shown to be safe and efficacious for up to 120 weeks in Part A. Here we report results from Part B, which evaluated safety and efficacy for an additional 96 weeks. Methods: Part B enrolled participants aged & GE;12 years with CF and F/F or F/RF genotypes who completed TEZ/IVA treatment in either Study 661-110 Part A, Study 661-112 (F/F), or Study 661-114 (F/F). Participants received TEZ 100 mg/IVA 150 mg fixed-dose combination once daily (morning) and IVA 150 mg once daily (evening) for 96 weeks. Safety endpoints included adverse events (AEs) and serum liver function tests. Efficacy endpoints included absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) and pulmonary exacerbation (PEx) rate. Results: 464 participants were enrolled from Part A (n = 377) and other eligible studies (n = 87); 463 re-ceived & GE;1 dose of TEZ/IVA. Overall, 92.2% had & GE;1 AE, 0.9% had AEs leading to treatment discontinuation, and 29.4% reported serious AEs. The most common AEs, which were generally consistent with common manifestations of CF, included infective PEx of CF, cough, nasopharyngitis, hemoptysis, and headache. Lung function was maintained over 96 weeks in both genotype groups. PEx rates per year were compa-rable with Part A. Conclusions: TEZ/IVA was generally safe and well tolerated over a further 96 weeks; safety data were consistent with Part A. Improvements in ppFEV1 and PEx rates were maintained for an additional 96 weeks in Part B. & COPY; 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：464 / 470

页数：7

共 15 条

[1]

[Anonymous], 2019, FDA APPR NEW BREAKTH

[2] The future of cystic fibrosis care: a global perspective [J].

Bell, Scott C. ;

Mall, Marcus A. ;

Gutierrez, Hector ;

Macek, Milan ;

Madge, Susan ;

Davies, Jane C. ;

Burgel, Pierre-Regis ;

Tullis, Elizabeth ;

Castaos, Claudio ;

Castellani, Carlo ;

Byrnes, Catherine A. ;

Cathcart, Fiona ;

Chotirmall, Sanjay H. ;

Cosgriff, Rebecca ;

Eichler, Irmgard ;

Fajac, Isabelle ;

Goss, Christopher H. ;

Drevinek, Pavel ;

Farrell, Philip M. ;

Gravelle, Anna M. ;

Havermans, Trudy ;

Mayer-Hamblett, Nicole ;

Kashirskaya, Nataliya ;

Kerem, Eitan ;

Mathew, Joseph L. ;

McKone, Edward F. ;

Naehrlich, Lutz ;

Nasr, Samya Z. ;

Oates, Gabriela R. ;

O'Neill, Ciaran ;

Pypops, Ulrike ;

Raraigh, Karen S. ;

Rowe, Steven M. ;

Southern, Kevin W. ;

Sivam, Sheila ;

Stephenson, Anne L. ;

Zampoli, Marco ;

Ratjen, Felix .

LANCET RESPIRATORY MEDICINE, 2020, 8 (01) :65-124

[3] A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect [J].

Boyle, Michael P. ;

De Boeck, Kris .

LANCET RESPIRATORY MEDICINE, 2013, 1 (02) :158-163

[4] Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice [J].

Castellani, C. ;

Cuppens, H. ;

Macek, M., Jr. ;

Cassinian, J. J. ;

Kerern, E. ;

Durie, P. ;

Tullis, E. ;

Assael, B. M. ;

Bombieri, C. ;

Brown, A. ;

Casals, T. ;

Claustres, M. ;

Cutting, G. R. ;

Dequeker, E. ;

Dodge, J. ;

Doull, I. ;

Farrell, P. ;

Ferec, C. ;

Girodon, E. ;

Johannesson, M. ;

Kerem, B. ;

Knowles, M. ;

Munck, A. ;

Pignatti, P. F. ;

Radojkovic, D. ;

Rizzotti, P. ;

Schwarz, M. ;

Stuhnnann, M. ;

Tzetis, M. ;

Zielenski, J. ;

Elborn, J. S. .

JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) :179-196

[5] Progress in therapies for cystic fibrosis [J].

De Boeck, Kris ;

Amaral, Margarida D. .

LANCET RESPIRATORY MEDICINE, 2016, 4 (08) :662-674

[6] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR [J].

Donaldson, Scott H. ;

Pilewski, Joseph M. ;

Griese, Matthias ;

Cooke, Jon ;

Viswanathan, Lakshmi ;

Tullis, Elizabeth ;

Davies, Jane C. ;

Lekstrom-Himes, Julie A. ;

Wang, Linda T. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) :214-224

[7] Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study [J].

Flume, Patrick A. ;

Biner, Reta Fischer ;

Downey, Damian G. ;

Brown, Cynthia ;

Jain, Manu ;

Fischer, Rainald ;

De Boeck, Kris ;

Sawicki, Gregory S. ;

Chang, Philip ;

Paz-Diaz, Hildegarde ;

Rubin, Jaime L. ;

Yang, Yoojung ;

Hu, Xingdi ;

Pasta, David J. ;

Millar, Stefanie J. ;

Campbell, Daniel ;

Wang, Xin ;

Ahluwalia, Neil ;

Owen, Caroline A. ;

Wainwright, Claire E. .

LANCET RESPIRATORY MEDICINE, 2021, 9 (07) :733-746

[8] Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [J].

Heijerman, Harry G. M. ;

McKone, Edward F. ;

Downey, Damian G. ;

Van Braeckel, Eva ;

Rowe, Steven M. ;

Tullis, Elizabeth ;

Mall, Marcus A. ;

Welter, John J. ;

Ramsey, Bonnie W. ;

Mckee, Charlotte M. ;

Marigowda, Gautham ;

Moskowitz, Samuel M. ;

Waltz, David ;

Sosnay, Patrick R. ;

Simard, Christopher ;

Ahluwalia, Neil ;

Xuan, Fengjuan ;

Zhang, Yaohua ;

Taylor-Cousar, Jennifer L. ;

Mccoy, Karen S. .

LANCET, 2019, 394 (10212) :1940-1948

[9] Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study [J].

Konstan, Michael W. ;

McKone, Edward F. ;

Moss, Richard B. ;

Marigowda, Gautham ;

Tian, Simon ;

Waltz, David ;

Huang, Xiaohong ;

Lubarsky, Barry ;

Rubin, Jaime ;

Millar, Stefanie J. ;

Pasta, David J. ;

Mayer-Hamblett, Nicole ;

Goss, Christopher H. ;

Morgan, Wayne ;

Sawicki, Gregory S. .

LANCET RESPIRATORY MEDICINE, 2017, 5 (02) :107-118

[10]

McKone EF, 2014, LANCET RESP MED, V2, P902, DOI [10.1016/s2213-2600(14)70218-8, 10.1016/S2213-2600(14)70218-8]

← 1 2 →